| 000 | 01579 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513212608.0 | ||
| 264 | 0 | _c20000706 | |
| 008 | 200007s 0 0 eng d | ||
| 022 | _a1084-9785 | ||
| 024 | 7 |
_a10.1089/cbr.1998.13.165 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDillman, R O | |
| 245 | 0 | 0 |
_aClinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. _h[electronic resource] |
| 260 |
_bCancer biotherapy & radiopharmaceuticals _cJun 1998 |
||
| 300 |
_a165-76 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBCG Vaccine _xtherapeutic use |
| 650 | 0 | 4 |
_aCancer Vaccines _xadverse effects |
| 650 | 0 | 4 |
_aCell Culture Techniques _xmethods |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aGranulocyte-Macrophage Colony-Stimulating Factor _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHypersensitivity, Delayed |
| 650 | 0 | 4 |
_aInterferons _xtherapeutic use |
| 650 | 0 | 4 |
_aMelanoma _ximmunology |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 700 | 1 | _aNayak, S K | |
| 700 | 1 | _aBarth, N M | |
| 700 | 1 | _aDeLeon, C | |
| 700 | 1 | _aSchwartzberg, L S | |
| 700 | 1 | _aSpitler, L E | |
| 700 | 1 | _aChurch, C | |
| 700 | 1 | _aO'Connor, A A | |
| 700 | 1 | _aBeutel, L D | |
| 773 | 0 |
_tCancer biotherapy & radiopharmaceuticals _gvol. 13 _gno. 3 _gp. 165-76 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/cbr.1998.13.165 _zAvailable from publisher's website |
| 999 |
_c10801453 _d10801453 |
||